L. Becquemont, A. Alfirevic, U. Amstutz, H. Brauch, E. Jacqz-aigrain et al., Practical recommendations for pharmacogenomics-based prescription: 2010 ESF???UB Conference on Pharmacogenetics and Pharmacogenomics, Pharmacogenomics, vol.12, issue.1, 2011.
DOI : 10.2217/pgs.10.147

P. Marquet, N. Djebli, and N. Picard, Pharmacog??n??tique des m??dicaments immunosuppresseurs, Annales Pharmaceutiques Fran??aises, vol.65, issue.6, pp.382-391, 2007.
DOI : 10.1016/S0003-4509(07)74197-4

W. Sadee, Pharmacogenomic biomarkers: validation needed for both the molecular genetic mechanism and clinical effect, Pharmacogenomics, vol.12, issue.5, pp.675-80, 2011.
DOI : 10.2217/pgs.11.23

A. Westlind, L. Löfberg, N. Tindberg, T. Andersson, and M. Ingelman-sundberg, Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5???-Upstream Regulatory Region, Biochemical and Biophysical Research Communications, vol.259, issue.1, pp.201-206, 1999.
DOI : 10.1006/bbrc.1999.0752

V. Ozdemir, W. Kalow, B. Tang, A. Paterson, S. Walker et al., Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method, Pharmacogenetics, vol.10, issue.5, pp.373-88, 2000.
DOI : 10.1097/00008571-200007000-00001

A. Westlind-johnsson, R. Hermann, A. Huennemeyer, B. Hauns, G. Lahu et al., Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity, Clinical Pharmacology & Therapeutics, vol.79, issue.4, pp.339-388, 2006.
DOI : 10.1016/j.clpt.2005.11.015

C. Wandel, J. Witte, J. Hall, C. Stein, A. Wood et al., CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5???-promoter region polymorphism, Clinical Pharmacology & Therapeutics, vol.68, issue.1, pp.82-91, 2000.
DOI : 10.1067/mcp.2000.108506

J. Lamba, Y. Lin, K. Thummel, A. Daly, P. Watkins et al., Common allelic variants of cytochrome P4503A4 and their prevalence in different populations, Pharmacogenetics, vol.12, issue.2, pp.121-153, 2002.
DOI : 10.1097/00008571-200203000-00006

E. García-martín, C. Martínez, R. Pizarro, F. García-gamito, H. Gullsten et al., CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity, Clinical Pharmacology & Therapeutics, vol.71, issue.3, pp.196-204, 2002.
DOI : 10.1067/mcp.2002.121371

B. Sinues, J. Vicente, A. Fanlo, P. Vasquez, J. Medina et al., CYP3A5*3 and CYP3A4*1B Allele Distribution and Genotype Combinations: Differences Between Spaniards and Central Americans, Therapeutic Drug Monitoring, vol.29, issue.4, pp.412-418, 2007.
DOI : 10.1097/FTD.0b013e31811f390a

D. Hesselink, T. Van-gelder, R. Van-schaik, A. Balk, I. Van-der-heiden et al., Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the and genes, Clinical Pharmacology & Therapeutics, vol.76, issue.6, pp.545-56, 2004.
DOI : 10.1016/j.clpt.2004.08.022

L. Wojnowski, E. Hustert, K. Klein, M. Goldammer, M. Haberl et al., Re: Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4, CancerSpectrum Knowledge Environment, vol.94, issue.8, pp.630-631, 2002.
DOI : 10.1093/jnci/94.8.630

I. Koch, R. Weil, R. Wolbold, J. Brockmöller, E. Hustert et al., Interindividual Variability and Tissue-Specificity in the Expression of Cytochrome P450 3A mRNA, Drug Metabolism and Disposition, vol.30, issue.10, pp.1108-1122, 2002.
DOI : 10.1124/dmd.30.10.1108

B. Amirimani, B. Ning, A. Deitz, B. Weber, F. Kadlubar et al., Increased transcriptional activity of theCYP3A4*1B promoter variant, Environmental and Molecular Mutagenesis, vol.259, issue.4, pp.299-305, 2003.
DOI : 10.1002/em.10199

D. Anglicheau, C. Legendre, P. Beaune, and E. Thervet, polymorphisms and immunosuppressive drugs: an update, Pharmacogenomics, vol.8, issue.7, pp.835-884, 2007.
DOI : 10.2217/14622416.8.7.835

M. Kurzawski, J. D?browska, K. Dziewanowski, L. Doma?ski, M. Peru?y?ska et al., polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients, Pharmacogenomics, vol.15, issue.2, pp.179-88, 2014.
DOI : 10.2217/pgs.13.199

L. Zhou, F. Yao, H. Luan, Y. Wang, X. Dong et al., CYP3A4*1B polymorphism and cancer risk: A HuGE review and meta-analysis, Tumor Biology, vol.27, issue.2, pp.649-60, 2013.
DOI : 10.1007/s13277-012-0592-z

A. Spurdle, B. Goodwin, E. Hodgson, J. Hopper, X. Chen et al., The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer, Pharmacogenetics, vol.12, issue.5, pp.355-66, 2002.
DOI : 10.1097/00008571-200207000-00003

D. Wang and W. Sadee, The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy, Journal of Personalized Medicine, vol.2, issue.4
DOI : 10.3390/jpm2040175

D. Wang, Y. Guo, S. Wrighton, G. Cooke, and W. Sadee, Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs, The Pharmacogenomics Journal, vol.34, issue.4, pp.274-86, 2011.
DOI : 10.2217/pgs.09.42

X. Zuo, C. Ng, J. Barrett, A. Luo, B. Zhang et al., Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients, Pharmacogenetics and Genomics, vol.23, issue.5, pp.251-61, 2013.
DOI : 10.1097/FPC.0b013e32835fcbb6

S. Sim and M. Ingelman-sundberg, Update on Allele Nomenclature for Human Cytochromes P450 and the Human Cytochrome P450 Allele (CYP-Allele) Nomenclature Database, Methods Mol Biol Clifton NJ, vol.987, pp.251-260, 2013.
DOI : 10.1007/978-1-62703-321-3_21

F. Sata, A. Sapone, G. Elizondo, P. Stocker, V. Miller et al., CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity, Clinical Pharmacology & Therapeutics, vol.67, issue.1, pp.48-56, 2000.
DOI : 10.1067/mcp.2000.104391

N. Knops, E. Levtchenko, B. Van-den-heuvel, and D. Kuypers, From gut to kidney: Transporting and metabolizing calcineurin-inhibitors in solid organ transplantation, International Journal of Pharmaceutics, vol.452, issue.1-2, pp.14-35, 2013.
DOI : 10.1016/j.ijpharm.2013.05.033

M. Miyazaki, K. Nakamura, Y. Fujita, F. Guengerich, R. Horiuchi et al., Defective Activity of Recombinant Cytochromes P450 3A4.2 and 3A4.16 in Oxidation of Midazolam, Nifedipine, and Testosterone, Drug Metabolism and Disposition, vol.36, issue.11, pp.2287-91, 2008.
DOI : 10.1124/dmd.108.021816

S. Crettol, J. Venetz, M. Fontana, J. Aubert, M. Pascual et al., CYP3A7, CYP3A5, CYP3A4, and ABCB1 Genetic Polymorphisms, Cyclosporine Concentration, and Dose Requirement in Transplant Recipients, Therapeutic Drug Monitoring, vol.30, issue.6, p.68999, 2008.
DOI : 10.1097/FTD.0b013e31818a2a60

O. Sharaki, M. Zeid, P. Moez, N. Zakaria, and E. Nassar, Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients, Molecular Biology Reports, vol.64, issue.2, pp.105-122, 2015.
DOI : 10.1007/s11033-014-3747-8

X. Qiu, Z. Jiao, M. Zhang, L. Zhong, H. Liang et al., Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients, European Journal of Clinical Pharmacology, vol.35, issue.5, pp.1069-84, 2008.
DOI : 10.1007/s00228-008-0520-8

H. Xin, H. Liu, Y. Li, H. Huang, L. Zhang et al., Association of CYP3A4*18B and CYP3A5*3 polymorphism with cyclosporine-related liver injury in Chinese renal transplant recipients, Int. Journal of Clinical Pharmacology and Therapeutics, vol.52, issue.06, pp.497-503, 2014.
DOI : 10.5414/CP202042

D. Li, R. Teng, H. Zhu, and Y. Fang, CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients, Int. Journal of Clinical Pharmacology and Therapeutics, vol.51, issue.06, pp.466-74, 2013.
DOI : 10.5414/CP201836

D. Anglicheau, E. Thervet, I. Etienne, H. De-ligny, B. et al., CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation, Clinical Pharmacology & Therapeutics, vol.75, issue.5, pp.422-455, 2004.
DOI : 10.1016/j.clpt.2004.01.009

V. Ahsen, N. Richter, M. Grupp, C. Ringe, B. Oellerich et al., No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients, Clin Chem. juin, vol.47, issue.6, pp.1048-52, 2001.

T. Kronbach, V. Fischer, and U. Meyer, Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs, Clinical Pharmacology and Therapeutics, vol.43, issue.6, pp.630-635, 1988.
DOI : 10.1038/clpt.1988.87

D. Hesselink, R. Van-schaik, I. Van-der-heiden, M. Van-der-werf, P. Gregoor et al., Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus, Clinical Pharmacology & Therapeutics, vol.74, issue.3, pp.245-54, 2003.
DOI : 10.1016/S0009-9236(03)00168-1

R. Bouamar, D. Hesselink, R. Van-schaik, W. Weimar, I. Macphee et al., Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are Not Associated With Cyclosporine Pharmacokinetics Nor With Cyclosporine Clinical End Points After Renal Transplantation, Therapeutic Drug Monitoring, vol.33, issue.2, pp.178-84, 2011.
DOI : 10.1097/FTD.0b013e31820feb8e

D. Min and V. Ellingrod, Association of the CYP3A4*1B 5??-Flanking Region Polymorphism With Cyclosporine Pharmacokinetics in Healthy Subjects, Therapeutic Drug Monitoring, vol.25, issue.3, pp.305-314, 2003.
DOI : 10.1097/00007691-200306000-00010

D. ?ochowska, J. Wyzga?, and L. P?czek, Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients, Ann Transplant Q Pol Transplant Soc. sept, vol.17, issue.3, pp.36-44, 2012.

I. Lunde, S. Bremer, K. Midtvedt, B. Mohebi, M. Dahl et al., The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients, European Journal of Clinical Pharmacology, vol.4, issue.3, pp.685-93, 2014.
DOI : 10.1007/s00228-014-1656-3

L. Elens, M. Becker, V. Haufroid, A. Hofman, L. Visser et al., Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study, Pharmacogenetics and Genomics, vol.21, issue.12, pp.861-867, 2011.
DOI : 10.1097/FPC.0b013e32834c6edb

P. Loh, H. Lou, Y. Zhao, Y. Chin, and A. Vathsala, Significant Impact of Gene Polymorphisms on Tacrolimus But Not Cyclosporine Dosing in Asian Renal Transplant Recipients, Transplantation Proceedings, vol.40, issue.5, pp.1690-1695, 2008.
DOI : 10.1016/j.transproceed.2008.04.010

D. A. Moes, J. Swen, J. Den-hartigh, T. Van-der-straaten, J. Van-der-heide et al., Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation, p.100, 2014.
DOI : 10.1016/j.cmpb.2010.04.018

L. Elens, T. Van-gelder, D. Hesselink, V. Haufroid, and R. Van-schaik, variant allele for personalizing pharmacotherapy, Pharmacogenomics, vol.14, issue.1, pp.47-62, 2013.
DOI : 10.2217/pgs.12.187

L. Elens, A. Capron, R. Van-schaik, D. Meyer, M. et al., Impact of CYP3A4*22 Allele on Tacrolimus Pharmacokinetics in Early Period After Renal Transplantation, Therapeutic Drug Monitoring, vol.35, issue.5, pp.608-624, 2013.
DOI : 10.1097/FTD.0b013e318296045b

L. Elens, D. Hesselink, R. Van-schaik, and T. Van-gelder, allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations, British Journal of Clinical Pharmacology, vol.13, issue.6, pp.1545-1552, 2013.
DOI : 10.1111/bcp.12038

M. Naesens, E. Lerut, H. De-jonge, B. Van-damme, Y. Vanrenterghem et al., Donor Age and Renal P-Glycoprotein Expression Associate with Chronic Histological Damage in Renal Allografts, Journal of the American Society of Nephrology, vol.20, issue.11, pp.2468-80, 2009.
DOI : 10.1681/ASN.2009020192

Y. Shi, Y. Li, J. Tang, J. Zhang, Y. Zou et al., Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients, Gene, vol.512, issue.2, pp.226-257, 2013.
DOI : 10.1016/j.gene.2012.10.048

V. Gijsen, P. Madadi, M. Dube, D. Hesselink, G. Koren et al., Tacrolimusinduced nephrotoxicity and genetic variability: a review, Ann Transplant Q Pol Transplant Soc. juin, vol.17, issue.2, pp.111-132, 2012.

Ö. Tapirdamaz, D. Hesselink, S. Bouazzaoui, M. Azimpour, B. Hansen et al., Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation, Pharmacogenetics and Genomics, vol.24, issue.9, pp.427-462, 2014.
DOI : 10.1097/FPC.0000000000000063

S. Mizuno, K. Nakatani, Y. Muraki, A. Tanemura, Y. Azumi et al., Combination assays for evaluation of immune function and CYP3A5 genotype to identify the risk of infectious complications and mortality in living donor liver transplant patients, Ann Transplant Q Pol Transplant Soc, vol.18, pp.349-57, 2013.

F. Xue, L. Han, Y. Chen, Z. Xi, Q. Li et al., genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients, Pediatric Transplantation, vol.18, issue.2, pp.166-76, 2014.
DOI : 10.1111/petr.12216

N. Shuker, T. Van-gelder, and D. Hesselink, Intra-patient variability in tacrolimus exposure: Causes, consequences for clinical management, Transplantation Reviews, vol.29, issue.2, pp.78-84, 2015.
DOI : 10.1016/j.trre.2015.01.002

M. Goto, S. Masuda, T. Kiuchi, Y. Ogura, F. Oike et al., CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation, Pharmacogenetics, vol.14, issue.7, pp.471-479, 2004.
DOI : 10.1097/01.fpc.0000114747.08559.49

W. Wei-lin, J. Jing, Z. Shu-sen, L. Wu, L. Ting-bo et al., Tacrolimus dose requirement in relation to donor and recipient A B C B 1 a n d C Y P 3 A 5 g e n e polymorphisms in Chinese liver transplant patients, Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. mai, vol.12, issue.5, pp.775-80, 2006.

S. Yu, L. Wu, J. J. Yan, S. Jiang, G. Xie et al., Influence of CYP3A5 Gene Polymorphisms of Donor Rather than Recipient to Tacrolimus Individual Dose Requirement in Liver Transplantation, Transplantation, vol.81, issue.1, pp.46-51, 2006.
DOI : 10.1097/01.tp.0000188118.34633.bf

A. Provenzani, M. Notarbartolo, M. Labbozzetta, P. Poma, F. Biondi et al., The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients, Ann Transplant Q Pol Transplant Soc. mars, vol.14, issue.1, pp.23-31, 2009.

A. Provenzani, M. Notarbartolo, M. Labbozzetta, P. Poma, G. Vizzini et al., Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients, International Journal of Molecular Medicine, vol.28, issue.6, pp.1093-102, 2011.
DOI : 10.3892/ijmm.2011.794

P. Durand, D. Debray, M. Kolaci, J. Bouligand, V. Furlan et al., gene polymorphism, Pharmacogenomics, vol.14, issue.9, pp.1017-1042, 2013.
DOI : 10.2217/pgs.13.87

V. Guy-viterbo, H. Baudet, L. Elens, V. Haufroid, F. Lacaille et al., genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach, Pharmacogenomics, vol.15, issue.9, pp.1207-1228, 2014.
DOI : 10.2217/pgs.14.75

C. Staatz, L. Goodman, and S. Tett, Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I, Clinical Pharmacokinetics, vol.14, issue.7, pp.141-75, 2010.
DOI : 10.2165/11317350-000000000-00000

C. Staatz, L. Goodman, and S. Tett, Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II, Clinical Pharmacokinetics, vol.14, issue.11, pp.207-228, 2010.
DOI : 10.2165/11317550-000000000-00000

J. Woillard, J. Rerolle, N. Picard, A. Rousseau, A. Guillaudeau et al., Donor P-gp Polymorphisms Strongly Influence Renal Function and Graft Loss in a Cohort of Renal Transplant Recipients on Cyclosporine Therapy in a Long-Term Follow-Up, Clinical Pharmacology & Therapeutics, vol.50, issue.1, pp.95-100, 2010.
DOI : 10.1086/379378
URL : https://hal.archives-ouvertes.fr/inserm-00462541

S. Bandur, J. Petrasek, P. Hribova, E. Novotna, I. Brabcova et al., Haplotypic Structure of ABCB1/MDR1 Gene Modifies the Risk of the Acute Allograft Rejection in Renal Transplant Recipients, Transplantation, vol.86, issue.9, pp.1206-1219, 2008.
DOI : 10.1097/TP.0b013e318187c4d1

L. Elens, T. Van-gelder, D. Hesselink, V. Haufroid, and R. Van-schaik, variant allele for personalizing pharmacotherapy, Pharmacogenomics, vol.14, issue.1, pp.47-62, 2013.
DOI : 10.2217/pgs.12.187

L. Elens, R. Van-schaik, N. Panin, M. De-meyer, P. Wallemacq et al., polymorphism on calcineurin inhibitors??? dose requirements and trough blood levels in stable renal transplant patients, Pharmacogenomics, vol.12, issue.10, pp.1383-96, 2011.
DOI : 10.2217/pgs.11.90

A. Moes, D. Hesselink, R. Zietse, R. Van-schaik, T. Van-gelder et al., Calcineurin inhibitors and hypertension: a role for pharmacogenetics?, Pharmacogenomics, vol.15, issue.9, pp.1243-51, 2014.
DOI : 10.2217/pgs.14.87

H. Zhu, S. Yuan, Y. Fang, X. Sun, H. Kong et al., The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis, The Pharmacogenomics Journal, vol.11, issue.3, pp.237-283, 2011.
DOI : 10.2165/11313380-000000000-00000

K. Benkali, L. Rostaing, A. Premaud, J. Woillard, F. Saint-marcoux et al., Population Pharmacokinetics and Bayesian Estimation of Tacrolimus Exposure in Renal Transplant Recipients on a New Once-Daily Formulation, Clinical Pharmacokinetics, vol.41, issue.5, pp.683-92, 2010.
DOI : 10.2165/11535950-000000000-00000
URL : https://hal.archives-ouvertes.fr/inserm-00926496

E. Thervet, M. Loriot, S. Barbier, M. Buchler, M. Ficheux et al., Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing, Clinical Pharmacology & Therapeutics, vol.87, issue.6, pp.721-727, 2010.
DOI : 10.1097/00007890-200212150-00002

L. Elens, R. Bouamar, N. Shuker, D. Hesselink, T. Van-gelder et al., Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks, British Journal of Clinical Pharmacology, vol.7, issue.Suppl. 1, pp.715-743, 2014.
DOI : 10.1111/bcp.12253

L. Elens, D. Hesselink, R. Bouamar, K. Budde, J. De-fijter et al., Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine a in Renal Transplant Patients, Therapeutic Drug Monitoring, vol.36, issue.1, pp.71-80, 2014.
DOI : 10.1097/FTD.0b013e31829da6dd

M. Uesugi, M. Hosokawa, H. Shinke, E. Hashimoto, T. Takahashi et al., Influence of Cytochrome P450 (CYP) 3A4*1G Polymorphism on the Pharmacokinetics of Tacrolimus, Probability of Acute Cellular Rejection, and mRNA Expression Level of CYP3A5 Rather than CYP3A4 in Living-Donor Liver Transplant Patients, Biological and Pharmaceutical Bulletin, vol.36, issue.11, pp.1814-1835, 2013.
DOI : 10.1248/bpb.b13-00509

A. Demetris, K. Ruppert, I. Dvorchik, A. Jain, M. Minervini et al., Real-time monitoring of acute liver-allograft rejection using the Banff schema1, Transplantation, vol.74, issue.9, pp.1290-1296, 2002.
DOI : 10.1097/00007890-200211150-00016

A. Demetris, D. Adams, C. Bellamy, K. Blakolmer, A. Clouston et al., Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel, Hepatol Baltim Md. mars, vol.31, issue.3, pp.792-801, 2000.

V. Menon, J. Kopple, X. Wang, G. Beck, A. Collins et al., Effect of a Very Low-Protein Diet on Outcomes: Long-term Follow-up of the Modification of Diet in Renal Disease (MDRD) Study, American Journal of Kidney Diseases, vol.53, issue.2, pp.208-225, 2009.
DOI : 10.1053/j.ajkd.2008.08.009

M. Fukudo, Individualized Dosage Regimen of Immunosuppressive Drugs Based on Pharmacokinetic and Pharmacodynamic Analysis, YAKUGAKU ZASSHI, vol.127, issue.7, pp.1081-1090, 2007.
DOI : 10.1248/yakushi.127.1081

S. Yoon, J. Cho, O. Kwon, J. Choi, S. Park et al., CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). Transplantation. 27 mars 2013, pp.828-862

J. Buendia, G. Bramuglia, and C. Staatz, Effects of Combinational CYP3A5 6986A>G Polymorphism in Graft Liver and Native Intestine on the Pharmacokinetics of Tacrolimus in Liver Transplant Patients, Therapeutic Drug Monitoring, vol.36, issue.4, pp.442-449, 2014.
DOI : 10.1097/FTD.0000000000000032

H. Tang, H. Xie, Y. Yao, and Y. Hu, Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers, Pharmacogenetics and Genomics, vol.21, issue.11, pp.713-733, 2011.
DOI : 10.1097/FPC.0b013e32834a48ca

L. Rojas, M. Herrero, V. Bosó, M. García-eliz, J. Poveda et al., Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation, Pharmacogenetics and Genomics, vol.23, issue.10, pp.509-526, 2013.
DOI : 10.1097/FPC.0b013e3283642fb3

P. Durand, D. Debray, M. Kolaci, J. Bouligand, V. Furlan et al., gene polymorphism, Pharmacogenomics, vol.14, issue.9, pp.1017-1042, 2013.
DOI : 10.2217/pgs.13.87

D. Hesselink, R. Bouamar, L. Elens, R. Van-schaik, and T. Van-gelder, The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation, Clinical Pharmacokinetics, vol.364, issue.Suppl. 1, pp.123-162, 2014.
DOI : 10.1007/s40262-013-0120-3

D. Wang and W. Sadee, The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy, Journal of Personalized Medicine, vol.2, issue.4
DOI : 10.3390/jpm2040175

J. Jia, B. Lin, J. He, L. Geng, D. Kadel et al., ''Minimizing tacrolimus'' strategy and long-term survival after liver transplantation, World Journal of Gastroenterology, vol.20, issue.32, pp.11363-11372, 2014.
DOI : 10.3748/wjg.v20.i32.11363

C. Gerard, J. Stocco, A. Hulin, B. Blanchet, C. Verstuyft et al., Determination of the Most Influential Sources of Variability in Tacrolimus Trough Blood Concentrations in Adult Liver Transplant Recipients: A Bottom-Up Approach, The AAPS Journal, vol.16, issue.3, pp.379-91, 2014.
DOI : 10.1208/s12248-014-9577-8

A. Capron, M. Mourad, D. Meyer, M. , D. Pauw et al., polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation, Pharmacogenomics, vol.11, issue.5, pp.703-717, 2010.
DOI : 10.2217/pgs.10.43

Y. Chen, L. Han, F. Xue, C. Shen, J. Lu et al., Personalized Tacrolimus Dose Requirement by CYP3A5 but Not ABCB1 or ACE Genotyping in Both Recipient and Donor after Pediatric Liver Transplantation, PLoS ONE, vol.37, issue.10, p.109464, 2014.
DOI : 10.1371/journal.pone.0109464.t005

M. Goto, S. Masuda, H. Saito, S. Uemoto, T. Kiuchi et al., C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation, Pharmacogenetics, vol.12, issue.6, pp.451-458, 2002.
DOI : 10.1097/00008571-200208000-00005

M. Fukudo, I. Yano, A. Yoshimura, S. Masuda, M. Uesugi et al., Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients, Pharmacogenetics and Genomics, vol.18, issue.5, pp.413-436, 2008.
DOI : 10.1097/FPC.0b013e3282f9ac01

S. Masuda, M. Goto, M. Okuda, Y. Ogura, F. Oike et al., Initial Dosage Adjustment for Oral Administration of Tacrolimus Using the Intestinal MDR1 Level in Living-Donor Liver Transplant Recipients, Transplantation Proceedings, vol.37, issue.4, pp.1728-1737, 2005.
DOI : 10.1016/j.transproceed.2005.02.081

T. Hashida, S. Masuda, S. Uemoto, H. Saito, K. Tanaka et al., Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation, Clinical Pharmacology & Therapeutics, vol.69, issue.5, pp.308-324, 2001.
DOI : 10.1067/mcp.2001.115142

S. Masuda, M. Goto, S. Fukatsu, M. Uesugi, Y. Ogura et al., Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients, Clinical Pharmacology & Therapeutics, vol.79, issue.1, pp.90-102, 2006.
DOI : 10.1016/j.clpt.2005.09.013

Y. Li, X. Hu, B. Cai, J. Chen, Y. Bai et al., Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients, Transplant Immunology, vol.27, issue.1, pp.12-20, 2012.
DOI : 10.1016/j.trim.2012.03.006

L. Elens, A. Capron, V. Kerckhove, J. Lerut, M. Mourad et al., 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation, Pharmacogenetics and Genomics, vol.17, issue.10, pp.873-83, 2007.
DOI : 10.1097/FPC.0b013e3282e9a533

W. Wei-lin, J. Jing, Z. Shu-sen, L. Wu, L. Ting-bo et al., Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients, Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. mai, vol.12, issue.5, pp.775-80, 2006.

M. Gómez-bravo, M. Salcedo, C. Fondevila, F. Suarez, J. Castellote et al., Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients, The Journal of Clinical Pharmacology, vol.40, issue.4, pp.1146-54, 2013.
DOI : 10.1002/jcph.154

N. Kamar, C. Guilbeau-frugier, A. Servais, I. Tack, E. Thervet et al., Kidney histology and function in liver transplant patients, Nephrology Dialysis Transplantation, vol.26, issue.7, pp.2355-61, 2011.
DOI : 10.1093/ndt/gfq718

A. Pawarode, D. Fine, and P. Thuluvath, Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc, juill, vol.9, issue.7, pp.741-748, 2003.

S. Nair, S. Verma, and P. Thuluvath, Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation, Hepatology, vol.5, issue.5, pp.1179-85, 2002.
DOI : 10.1053/jhep.2002.33160

M. Weber, H. Ibrahim, and J. Lake, Renal dysfunction in liver transplant recipients: Evaluation of the critical issues, Liver Transplantation, vol.8, issue.pt 2, pp.1290-301, 2012.
DOI : 10.1002/lt.23522

A. Hawwa, P. Mckiernan, M. Shields, J. Millership, P. Collier et al., Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant, British Journal of Clinical Pharmacology, vol.79, issue.1, pp.413-434, 2009.
DOI : 10.1111/j.1365-2125.2009.03461.x

A. Hawwa and J. Mcelnay, Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant, Expert Opinion on Drug Safety, vol.4, issue.1, pp.9-22, 2011.
DOI : 10.1016/S0140-6736(03)12715-8

A. Moutabarrik, M. Ishibashi, H. Kameoka, N. Kawaguchi, Y. Takano et al., In vitro FK506 kidney tubular cell toxicity, Transpl Int Off J Eur Soc Organ Transplant, vol.5, 1992.
DOI : 10.1007/978-3-642-77423-2_29

C. Abrass, A. Berfield, C. Stehman-breen, C. Alpers, and C. Davis, Unique changes in interstitial extracellular matrix composition are associated with rejection and cyclosporine toxicity in human renal allograft biopsies, American Journal of Kidney Diseases, vol.33, issue.1, pp.11-20, 1999.
DOI : 10.1016/S0272-6386(99)70252-0

M. Hebert, A. Dowling, C. Gierwatowski, Y. Lin, K. Edwards et al., Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors, Pharmacogenetics, vol.13, issue.11, pp.661-74, 2003.
DOI : 10.1097/00008571-200311000-00002

I. Hauser, E. Schaeffeler, S. Gauer, E. Scheuermann, B. Wegner et al., ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporinerelated nephrotoxicity after renal transplantation. J A m S o c N e p h r o l J A S N, pp.1501-1512, 2005.

D. Cattaneo, P. Ruggenenti, S. Baldelli, N. Motterlini, E. Gotti et al., ABCB1 Genotypes Predict Cyclosporine-Related Adverse Events and Kidney Allograft Outcome, Journal of the American Society of Nephrology, vol.20, issue.6, pp.1404-1419, 2009.
DOI : 10.1681/ASN.2008080819
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689900

J. Moore, A. Mcknight, B. Döhler, M. Simmonds, A. Courtney et al., Donor ABCB1 Variant Associates with Increased Risk for Kidney Allograft Failure, Journal of the American Society of Nephrology, vol.23, issue.11, pp.1891-1900, 2012.
DOI : 10.1681/ASN.2012030260

S. Hübscher, What is the long-term outcome of the liver allograft?, Journal of Hepatology, vol.55, issue.3, pp.702-719, 2011.
DOI : 10.1016/j.jhep.2011.03.005

A. Jalil, M. Hawwa, A. Mckiernan, P. Shields, M. et al., Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients, British Journal of Clinical Pharmacology, vol.64, issue.Suppl 1, pp.130-170, 2014.
DOI : 10.1111/bcp.12174

D. Adams, A. Sanchez-fueyo, and D. Samuel, From immunosuppression to tolerance, Journal of Hepatology, vol.62, issue.1
DOI : 10.1016/j.jhep.2015.02.042

D. Anglicheau, C. Legendre, and E. Thervet, Pharmacogenetics in Solid Organ Transplantation: Present Knowledge and Future Perspectives, Transplantation, vol.78, issue.3, pp.311-316, 2004.
DOI : 10.1097/01.TP.0000136256.56873.41

K. Blakolmer, A. Jain, K. Ruppert, E. Gray, R. Duquesnoy et al., CHRONIC LIVER ALLOGRAFT REJECTION IN A POPULATION TREATED PRIMARILY WITH TACROLIMUS AS BASELINE IMMUNOSUPPRESSION, Transplantation, vol.69, issue.11, pp.2330-2336, 2000.
DOI : 10.1097/00007890-200006150-00019

D. Chen, F. Guo, J. Shi, C. Zhang, Z. Wang et al., Association of Hemoglobin Levels, CYP3A5, and NR1I3 Gene Polymorphisms with Tacrolimus Pharmacokinetics in Liver Transplant Patients, Drug Metabolism and Pharmacokinetics, vol.29, issue.3, pp.249-53, 2014.
DOI : 10.2133/dmpk.DMPK-13-RG-095

H. De-jonge, L. Elens, H. De-loor, R. Van-schaik, and D. Kuypers, The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients, The Pharmacogenomics Journal, vol.35, issue.2, pp.144-52, 2015.
DOI : 10.1038/sj.clpt.6100216

P. Durand, D. Debray, M. Kolaci, J. Bouligand, V. Furlan et al., gene polymorphism, Pharmacogenomics, vol.14, issue.9, pp.1017-1042, 2013.
DOI : 10.2217/pgs.13.87

C. Duvoux, F. Roudot-thoraval, T. Decaens, F. Pessione, H. Badran et al., Liver Transplantation for Hepatocellular Carcinoma: A Model Including ??-Fetoprotein Improves the Performance of Milan Criteria, Gastroenterology, vol.143, issue.4, pp.98694-98697, 2012.
DOI : 10.1053/j.gastro.2012.05.052
URL : https://hal.archives-ouvertes.fr/inserm-00865368

L. Elens, T. Van-gelder, D. Hesselink, V. Haufroid, and R. Van-schaik, variant allele for personalizing pharmacotherapy, Pharmacogenomics, vol.14, issue.1, pp.47-62, 2013.
DOI : 10.2217/pgs.12.187

L. Elens, A. Nieuweboer, S. Clarke, K. Charles, A. De-graan et al., ) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin, Pharmacogenomics, vol.14, issue.2, pp.137-186, 2013.
DOI : 10.2217/pgs.12.202

M. García, R. Macías, J. Cubero, J. Benítez, and F. Caravaca, ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients, European Journal of Clinical Pharmacology, vol.22, issue.5, pp.385-93, 2013.
DOI : 10.1007/s00228-012-1355-x

C. Gérard, J. Stocco, A. Hulin, B. Blanchet, C. Verstuyft et al., Determination of the Most Influential Sources of Variability in Tacrolimus Trough Blood Concentrations in Adult Liver Transplant Recipients: A Bottom-Up Approach, The AAPS Journal, vol.16, issue.3, pp.379-91, 2014.
DOI : 10.1208/s12248-014-9577-8

G. Gervasini, M. Garcia, R. Macias, J. Cubero, F. Caravaca et al., Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation, Transplant International, vol.91, issue.4, pp.471-80, 2012.
DOI : 10.1111/j.1432-2277.2012.01446.x

V. Gijsen, D. Hesselink, K. Croes, G. Koren, and S. De-wildt, Prevalence of renal dysfunction in tacrolimus-treated pediatric transplant recipients: A systematic review, Pediatric Transplantation, vol.11, issue.3, pp.205-220, 2013.
DOI : 10.1111/petr.12056

V. Haufroid, M. Mourad, V. Van-kerckhove, J. Wawrzyniak, D. Meyer et al., The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients, Pharmacogenetics, vol.14, issue.3, pp.147-54, 2004.
DOI : 10.1097/00008571-200403000-00002

I. Hauser, E. Schaeffeler, S. Gauer, E. Scheuermann, B. Wegner et al., ABCB1 Genotype of the Donor but Not of the Recipient Is a Major Risk Factor for Cyclosporine-Related Nephrotoxicity after Renal Transplantation, Journal of the American Society of Nephrology, vol.16, issue.5, pp.1501-1512, 2005.
DOI : 10.1681/ASN.2004100882

M. Jalil, A. Hawwa, P. Mckiernan, M. Shields, and J. Mcelnay, Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients, British Journal of Clinical Pharmacology, vol.64, issue.Suppl 1, pp.130-170, 2014.
DOI : 10.1111/bcp.12174

E. Ji, L. Choi, K. Suh, J. Cho, N. Han et al., Combinational Effect of Intestinal and Hepatic CYP3A5 Genotypes on Tacrolimus Pharmacokinetics in Recipients of Living Donor Liver Transplantation, Transplantation Journal, vol.94, issue.8, pp.866-72, 2012.
DOI : 10.1097/TP.0b013e318263700a

M. Krönke, W. Leonard, J. Depper, S. Arya, F. Wong-staal et al., Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription., Proceedings of the National Academy of Sciences, vol.81, issue.16, pp.5214-5232
DOI : 10.1073/pnas.81.16.5214

W. Lemahieu, B. Maes, K. Verbeke, and Y. Vanrenterghem, CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs

D. Li, W. Lu, J. Zhu, J. Gao, Y. Lou et al., Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients, Journal of Clinical Pharmacy and Therapeutics, vol.80, issue.5, pp.505-520, 2007.
DOI : 10.1111/j.1365-2710.2007.00850.x

S. Liu, R. Frye, R. Branch, R. Venkataramanan, J. Fung et al., Effect of Age and Postoperative Time on Cytochrome P450 Enzyme Activity Following Liver Transplantation, The Journal of Clinical Pharmacology, vol.54, issue.Suppl 1, pp.666-73, 2005.
DOI : 10.1177/0091270005276202

Y. Liu, C. Li, Z. Cui, X. Fu, S. Zhang et al., The effect of ABCB1 C3435T polymorphism on pharmacokinetics of tacrolimus in liver transplantation: A meta-analysis, Gene, vol.531, issue.2
DOI : 10.1016/j.gene.2013.09.024

S. Masuda, M. Goto, T. Kiuchi, S. Uemoto, T. Kodawara et al., Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation. Liver Transplant Off Publ Am A s s o c S t u d y L i v e r D i s I n t L i v e r Transplant Soc, oct, vol.9, issue.10, pp.1108-1121, 2003.

M. Mourad, P. Wallemacq, D. Meyer, M. Malaise, J. et al., Biotransformation Enzymes and Drug Transporters Pharmacogenetics in Relation to Immunosuppressive Drugs: Impact on Pharmacokinetics and Clinical Outcome, Transplantation, vol.85, issue.Supplement, pp.19-24, 2008.
DOI : 10.1097/TP.0b013e318169c380

N. Picard and P. Marquet, The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation, Expert Opinion on Drug Metabolism & Toxicology, vol.35, issue.3, pp.731-774, 2011.
DOI : 10.1073/pnas.0506483102
URL : https://hal.archives-ouvertes.fr/inserm-00577136

L. Quteineh and C. Verstuyft, Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients, Current Opinion in Organ Transplantation, vol.15, issue.5, pp.601-608, 2010.
DOI : 10.1097/MOT.0b013e32833de1d0

W. Sadee, Pharmacogenomic biomarkers: validation needed for both the molecular genetic mechanism and clinical effect, Pharmacogenomics, vol.12, issue.5, pp.675-80, 2011.
DOI : 10.2217/pgs.11.23

T. Sakaeda, T. Nakamura, and K. Okumura, Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs, Pharmacogenomics, vol.4, issue.4, pp.397-410, 2003.
DOI : 10.1517/phgs.4.4.397.22747

M. Sebagh, K. Rifai, C. Feray, F. Yilmaz, B. Falissard et al., All liver recipients benefit from the protocol 10-year liver biopsies, Hepatology, vol.36, issue.6, pp.1293-301, 2003.
DOI : 10.1053/jhep.2003.50231

M. Sebagh, D. Samuel, T. Antonini, A. Coilly, D. Espositi et al., Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients, Journal of Hepatology, vol.56, issue.4, pp.840-847, 2012.
DOI : 10.1016/j.jhep.2011.11.016

C. Stein, A. Sadeque, J. Murray, C. Wandel, R. Kim et al., Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects, Clinical Pharmacology & Therapeutics, vol.69, issue.5, pp.317-340, 2001.
DOI : 10.1067/mcp.2001.115073

H. Tang, L. Ma, H. Xie, T. Zhang, and Y. Hu, Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis, Pharmacogenetics and Genomics, vol.20, issue.9
DOI : 10.1097/FPC.0b013e32833ccd56

B. Tavira, J. Gómez, C. Diaz-corte, B. Suarez, D. Coronel et al., Abstract, Clinical Chemistry and Laboratory Medicine (CCLM), vol.53, issue.10, 2015.
DOI : 10.1515/cclm-2014-1195

S. Turolo, A. Tirelli, M. Ferraresso, L. Ghio, M. Belingheri et al., Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation, Pharmacological Reports, vol.62, issue.6, pp.1159-69, 2010.
DOI : 10.1016/S1734-1140(10)70378-9

M. Uesugi, M. Kikuchi, H. Shinke, T. Omura, A. Yonezawa et al., Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation, Pharmacogenetics and Genomics, vol.24, issue.7, pp.356-66, 2014.
DOI : 10.1097/FPC.0000000000000060

K. Utecht, J. Hiles, and J. Kolesar, Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors, American Journal of Health-System Pharmacy, vol.63, issue.23, pp.2340-2348, 2006.
DOI : 10.2146/ajhp060080

M. Vicari-christensen, S. Repper, S. Basile, and D. Young, Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence, Progress in Transplantation, vol.18, issue.3, pp.277-84, 2009.
DOI : 10.7182/prtr.19.3.22u4114wn0l01140

D. Wang and W. Sadée, Searching for polymorphisms that affect gene expression and mRNA processing: Example ABCB1 (MDR1), The AAPS Journal, vol.8, issue.3, pp.515-535, 2006.
DOI : 10.1208/aapsj080361

W. Wei-lin, J. Jing, Z. Shu-sen, L. Wu, L. Ting-bo et al., Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients, Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. mai, vol.12, issue.5, pp.775-80, 2006.

L. Wu, X. Xu, J. Shen, H. Xie, S. Yu et al., MDR1 gene polymorphisms and risk of recurrence in patients With hepatocellular carcinoma after liver transplantation, Journal of Surgical Oncology, vol.10, issue.182, pp.62-70, 2007.
DOI : 10.1002/jso.20774

X. Yu, H. Xie, B. Wei, M. Zhang, W. Wang et al., Association of MDR1 Gene SNPs and Haplotypes with the Tacrolimus Dose Requirements in Han Chinese Liver Transplant Recipients, PLoS ONE, vol.6, issue.11, p.25933, 2011.
DOI : 10.1371/journal.pone.0025933.t005